Our findings support a robust dependency in MM on both BRD9 targeting and IKZF3 protein degradation, as simultaneous inhibition of both leads to marked MM cell killing with substantially higher potency than BRD9 targeting or IMiD treatment alone. This evidence concerns the gene IKZF3 and Miyoshi myopathy.